NCT00428792
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
See it on ClinicalTrials.gov ↗150 people
25.3%
74.7%
38 womenmiddle line = equal numbers112 men
- Phase
- PHASE3
- Paid for by
- Novartis
- Finished
- 2007-12
- Health conditions
- Attention Deficit Hyperactivity Disorder
- Who could join
- Anyone
- Ages
- 6 Years – 12 Years
- Average age
- mean 9.7 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 12 Years.”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Concomitant psychiatric disorders requiring pharmacological treatment”
Study titles and rules are shown in their original English.